Calcaneus Fracture Perioperative Complication Rates Lower with Application of CLARIX® Cryopreserved Umbilical Cord (cUC) Protection Status
Blog Category: 

By Industry News

Miami, FL – February 24, 2020 –Amniox Medical, Inc. (Amniox), a TissueTech, Inc. company and pioneer in the clinical application of human birth tissue-based products, announced today the results from a single-center, retrospective case-controlled series authored by Christopher M. Stewart, MD. The study, titled “The Use of Cryopreserved Umbilical Cord in Open Reduction and Internal Fixation of Calcaneus Fractures,” was published in the SunKrist Journal of Trauma, Emergency Medicine and Acute Care. Analysis found that the overall complication rate in a controlled group of 20 consecutive patients was 35 percent, compared to a complication rate of 10 percent in the cUC group of patients when CLARIX was used as an adjunct to help decrease wound complications, re-operations, and infection rates.

Wounds are disruptions of the skin’s structural and functional integrity and normally transition through distinct phases of healing until the skin’s structure and function are restored. Chronic wounds have failed to pass through the normal healing process. Patients with chronic wounds, such as diabetic foot ulcers and venous leg ulcers, experience loss of function, pain, wound recurrence, and significant morbidity. Care for chronic wounds involves removing necrotic tissue, applying dressings that maintain a moist wound environment, treating wound infections, and restoring blood flow to the wound site. If these procedures fail to restore the healing process, additional therapies may be considered.

Calcaneus (heel bone) fractures most often occur as a result of a traumatic event such as falling from a height, like a ladder, or being in an automobile accident where the heel is crushed against the floorboard. According to Joseph Ralph Cass, MD, FAAOS, and the American Academy of Orthopedic Surgeons, calcaneus fractures account for approximately 2 percent of all adult fractures.1 Although surgery to repair a calcaneus fracture can restore the normal shape of the bone, the procedure is sometimes associated with wound healing problems, infection or nerve damage.

Study results clearly showed lower complication rates in the cUC group of patients when CLARIX was used. In the group of 19 patients who received CLARIX, two patients required wound care postoperatively and two required readmission and re-operation for wound complications and infection. Conversely, in the group of 20 patients who did not receive CLARIX, seven patients required wound care postoperatively and six patients required readmission, with all six requiring re-operation for wound complications and infection.

“We are extremely encouraged by the results of this retrospective cohort study,” said Herbert Slade, MD, Chief Medical Officer at TissueTech. “The costs associated with wound complications, re-operations and surgical site infection after open reduction and internal fixation of calcaneal fractures can be significant. Finding that CLARIX Cryopreserved Umbilical Cord applied directly to the bone and hardware during surgery can reduce overall complications associated with this surgery. This is very promising for trauma surgeons and their patients. We look forward to being able to show the benefit of Amniox products for this and similar surgeries in larger studies powered for significance.”


About Amniox Medical, Inc.
Amniox Medical, Inc., a TissueTech, Inc. company, is a leader in the clinical application of human birth tissue-based products (amniotic membrane & umbilical cord) processed using TissueTech’s proprietary CryoTek® cryopreservation technology.

About TissueTech, Inc.
TissueTech, Inc., the parent company of Amniox Medical, Inc. and Bio-Tissue, Inc., is a scientific and market leader in the field of regenerative medicine. TissueTech manufactures a broad range of ocular, surgical, wound care, and soft tissue products that are marketed under these subsidiaries. Since the company’s inception, clinicians have performed more than 500,000 human implants of the company’s products and published more than 360 peer-reviewed studies supporting its platform technology. Learn more at

The views and opinions expressed in this blog are solely those of the author, and do not represent the views of WoundSource, Kestrel Health Information, Inc., its affiliates, or subsidiary companies.

Related company: 

Recommended for You

Important Notice: The contents of the website such as text, graphics, images, and other materials contained on the website ("Content") are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. The content is not intended to substitute manufacturer instructions. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or product usage. Refer to the Legal Notice for express terms of use.